Fuse H, Ando K, Hara S, Zama S, Shimazaki J
Hinyokika Kiyo. 1985 Feb;31(2):281-7.
From January, 1960 to March, 1984, we studied 65 cases of prostatic cancer resistant to endocrine therapy. Treatment with ifosfamide or combination chemotherapy with vincristine, ifosfamide and peplomycin was performed in some of the 65 cases above mentioned. More cases were systemic reactivation than local reactivation. Poorly differentiated cancer accounted for the majority of the reactivated cancer. Concerning adjacent effects, treatment with ifosfamide was superior to combination chemotherapy. There was no difference between the distant effects of both chemotherapies. The patients with no effects showed predominance of pathologically low differentiated cell type. The 6-month survival rate of patients with chemotherapy was significantly higher than that of patients with other therapies. Toxicities of chemotherapies were leucopenia, digestive disturbances and falling out of hair. Hematuria and pulmonary fibrosis occurred in some cases.
1960年1月至1984年3月，我们研究了65例对内分泌治疗耐药的前列腺癌患者。上述65例患者中的部分接受了异环磷酰胺治疗或长春新碱、异环磷酰胺及平阳霉素联合化疗。全身再激活的病例多于局部再激活。再激活的癌症中低分化癌占大多数。关于邻近效应，异环磷酰胺治疗优于联合化疗。两种化疗的远处效应无差异。无效患者中病理低分化细胞类型占优势。接受化疗患者的6个月生存率显著高于接受其他治疗的患者。化疗的毒性反应有白细胞减少、消化系统紊乱和脱发。部分病例出现血尿和肺纤维化。
